Reports

Drug name	NICE TAs	Comments
Tisagenlecleucel (Kymriah®)	TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years TA567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tivozanib	TA512 - Tivozanib for treating advanced renal cell carcinoma
Tocilizumab (Tyenne® Roactemra®)	TA247 - Rheumatoid arthritis - tocilizumab (rapid review TA198) TA238 - Tocilizumab for the treatment of systemic juvenile idiopathic arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis	Hospital use only
Tofacitinib (Xeljanz®)	TA547 - Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib (Xeljanz®)#10.2	TA480 - Tofacitinib for moderate to severe rheumatoid arthritis TA543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs TA735 - Tofacitinib for treating juvenile idiopathic arthritis TA920 - Tofacitinib for treating active ankylosing spondylitis
Tolvaptan (Jinarc®)	TA358 - Tolvaptan for treating autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease
Topotecan capsules	TA184 - Topotecan for the treatment of relapsed small-cell lung cancer	For hospital use only
Trametinib	TA396 - Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma TA544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab deruxtecan (Enhertu®)	TA704 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
Trastuzumab emtansine	TA34 - Guidance on the use of trastuzumab for the treatment of advanced breast cancer TA632 - Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports